Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series

J Eur Acad Dermatol Venereol. 2018 Jul;32(7):e274-e276. doi: 10.1111/jdv.14808. Epub 2018 Feb 27.

Authors

F Anzengruber^{1

2}, M Drach^{1

2}, J-T Maul^{1

2}, A G Kolios^{1

2

3}, B Meier^{1

2}, A A Navarini^{1

2}

Affiliations

¹ Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091, Zurich, Switzerland.
² Faculty of Medicine, University of Zurich, Pestalozzistrasse 3, 8091, Zurich, Switzerland.
³ Department of Immunology, University Hospital Zurich, Gloriastrasse 23, 8091, Zurich, Switzerland.

PMID: 29356172
DOI: 10.1111/jdv.14808

No abstract available

Publication types

Letter

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Dermatologic Agents / therapeutic use*
Female
Genotype
HLA-C Antigens / genetics*
Humans
Male
Middle Aged
Psoriasis / drug therapy*
Psoriasis / genetics*
Retrospective Studies
Young Adult

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Dermatologic Agents
HLA-C Antigens
HLA-C*06 antigen
secukinumab